The innovation and development of the traditional Chinese medicine industry is accelerating, and traditional Chinese medicine enterprises need to seize the opportunity

Recently, the Liaoning Provincial Food and Drug Administration and the Provincial Health Commission jointly issued the "Measures for Promoting the High-quality Inheritance, Innovation and Development of Traditional Chinese Medicine" (hereinafter referred to as the "Measures")
.
Specifically, the "Measures" are proposed from five aspects: encouraging R&D and innovation to promote the high-quality development of traditional Chinese medicine innovation, strengthening the management of traditional Chinese medicine and preparations in medical institutions, further strengthening the guidance of traditional Chinese medicine, strengthening the quality supervision during and after the event, and strengthening inter-departmental communication and coordination.
14 specific measures have been adopted to effectively strengthen the supervision of traditional Chinese medicine and promote the high-quality inheritance, innovation and development of traditional Chinese medicine in Liaoning Province
.
Coincidentally, on February 18, the Information Office of Zhejiang Provincial Government held a press conference on the medical insurance policy for the inheritance, innovation and development of traditional Chinese medicine in Zhejiang.
20 specific measures for medical insurance to support the development of traditional Chinese medicine are proposed in seven aspects, including hierarchical diagnosis and treatment, promotion of digital reform, development of traditional Chinese medicine industry, and improvement of fund performance
.
In addition, Wuxi City issued the "Several Measures for Promoting the Inheritance, Innovation and Development of Traditional Chinese Medicine", focusing on improving the traditional Chinese medicine service system, enhancing the traditional Chinese medicine service capacity, strengthening the gathering of traditional Chinese medicine talents, promoting the inheritance and development of the Longsha Medical School, and improving the traditional Chinese medicine department.
23 work measures were also put forward in eight aspects, including creating a system, promoting the development of traditional Chinese medicine entrepreneurship, promoting the excellent culture of traditional Chinese medicine, and improving the management system of traditional Chinese medicine
.
With the continuous favorable policies in various places, the industry generally believes that the traditional Chinese medicine industry will gain more opportunities in 2022
.
In fact, the traditional Chinese medicine sector has been very active recently, and many individual stocks have also experienced daily limit
.
Rulongjin Pharmaceutical has received several daily limit prices since this year
.
At 9:57 on February 14, Longjin Pharmaceutical once again closed the price limit at 13.
92 yuan, with a turnover of 488 million and a turnover rate of 9.
00%
.
However, it should be noted that with the rapid development of Chinese medicine industry innovation, analysts also pointed out that it should be noted that there are still many challenges in strengthening Chinese medicine, such as the shortage of high-level talents in traditional Chinese medicine, the low level of scientific and technological research and development, and the service system.
Inadequate perfection, insufficient development of traditional Chinese medicine culture, etc..
Among them, innovation is especially difficult, and research and development generally faces the problems of unclear mechanism of action and unclear active ingredients, which are seriously hindering the pace of inheritance, innovation and development of traditional Chinese medicine
.
In this regard, industry insiders said that in order to seize the opportunity and better promote the inheritance, innovation and development of traditional Chinese medicine, relevant companies need to grasp both the soft and the hard
.
On the one hand, the quality and innovation must be continuously improved; on the other hand, the publicity, promotion and management of traditional Chinese medicine must be strengthened
.
It is understood that many pharmaceutical companies have achieved remarkable results through long-term investment in innovation
.
For example, for a long time, Buchang Pharma has adhered to traditional Chinese medicine (including natural medicine) as the main line, based on the development strategy of Chinese medicine modernization, and continued to focus on exploration and innovation in the modernization of traditional Chinese medicine, modern Chinese medicine preparations, and modern Chinese medicine technology
.
At present, it has successfully developed and cultivated a number of well-known and exclusive varieties in the field of cardiovascular and cerebrovascular drugs, such as Naoxintong Capsule, Wenxin Granule, Danhong Injection and Guhong Injection.
have a certain advantage
.
In general, with the accelerated development of the traditional Chinese medicine industry, the industry expects that related companies in the industry chain will usher in more opportunities
.
In this context, for pharmaceutical companies, focusing on "software and hardware" will help make production management more efficient and convenient, and reduce costs; and gain more benefits in maintaining equipment, managing equipment, marketing, and services; and more Good help to promote the innovation and development of the entire Chinese medicine industry
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.